Type 2 diabetes. Diabetes mellitus due to underlying condition
Conditions
Interventions
Intervention 1: Intervention group: Patients with type 2 diabetes who will receive one tablet containing 1000 mg of vitamin C (ascorbic acid) daily for 4 consecutive weeks. These tablets are for oral
Sponsors
Birjand University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age between 30 and 65 years Definitive diagnosis of Type 2 Diabetes by a specialist physician (based on medical records or treatment history) according to the guidelines: Fasting Blood Sugar (FBS) greater than 126 mg/dL, or HbA1c greater than 6.5%. Stability of the diabetes control medication regimen within the past month Ability to cooperate in saliva sampling Written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Diagnosis of type 1 diabetes Use of antioxidant supplements (such as vitamins E, C, A, or folic acid) and medicated or antioxidant mouthwashes within the past month Presence of other chronic systemic diseases requiring long-term medication (such as kidney or liver diseases, or malignancies) Presence of severe diabetes complications (such as advanced retinopathy, neuropathy, or nephropathy) Regular abuse of alcohol or tobacco Presence of salivary gland diseases or conditions impairing salivary secretion, and active clinical symptoms of oral diseases (such as periodontitis, gingivitis, or mucosal lesions) Missed supplement intake more than twice a week Unwillingness to continue participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total antioxidant capacity of saliva. Timepoint: Before the start of the intervention and after the end of the intervention (4 weeks later). Method of measurement: The total antioxidant capacity of saliva will be measured using the FRAP (Ferric Reducing Antioxidant Power) method from Kavosh Aryan Azma Company. This method is based on the reduction of Fe³? (ferric) ions to Fe²? (ferrous) ions in the presence of the TPTZ (Triypridyl-S-Triazine) reagent, leading to the formation of a blue-colored Fe²?–TPTZ complex with absorbance at a wavelength of 593 nm. The color intensity is measured by a spectrophotometer and represents the antioxidant capacity of the sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSajjad Labbafi Esfahrood
Birjand University of Medical Sciences
Outcome results
None listed